Beginner's Mind

Most people still treat climate solutions as a cost. Wanwipa Siriwatwechakul argues that this is exactly why so many leaders miss the real opportunity. The next industrial era will not be built by patching old systems, but by redesigning them from the ground up. In this episode of Beginner’s Mind, Wanwipa explains why industrial decarbonization is not mainly about sacrifice, compliance, or adding expensive fixes to yesterday’s infrastructure. It is about building better systems, stronger companies, and entirely new categories of value creation. A chemical engineer trained at MIT and Princeton, former professor, and Partner at Vectors Capital, Wanwipa works at the intersection of climate tech, synthetic biology, industrial innovation, and early-stage venture capital. Her perspective is grounded in both science and scale: what matters is not only whether a breakthrough works in the lab, but whether it can survive the journey from one gram to one ton, from prototype to product, from curiosity to adoption. We talk about why the strongest climate companies redesign industries instead of decorating old ones, why synthetic biology is emerging as a new industrial toolkit, how startups like Huue Bio, Ingrediome, and Solidec reveal very different scale-up strategies, and why the best founders treat breakthroughs as hypotheses to test rather than theories to defend. As Wanwipa puts it: (01:57:02) “See climate solutions not as cost, but as funding the next industrial era.” What you’ll hear in this episode Selected moments (00:00:56) From Professor to Climate Tech Venture Capital (00:09:27) Why Climate Change Became Personal in Thailand (00:14:11) From Pure Discovery to Real Market Impact (00:23:00) Decarbonization by Redesigning Industry (00:30:06) The Climate Tech Mistake Costing Investors Money (00:34:17) Solidec and the Future of Distributed Manufacturing (00:38:50) Why Big Companies Resist Industrial Reinvention (00:46:21) How Great Founders Turn Pivots Into New Markets (00:50:50) Customer Discovery in Deep Tech and Climate Startups (00:53:08) Great Science Must Become Products People Use (01:00:39) Synthetic Biology as the New Industrial Toolkit (01:10:15) How Climate Startups Find Early Adopters (01:13:19) Founder Resilience and the Stomach of Steel (01:21:15) Venture Capital and the Crucial Why Now (01:57:02) Climate Solutions as Funding the Next Industrial Era Follow the show for more long-form conversations on technology Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

Power demand is rising faster than the systems meant to support it. AI, electrification, and industry all need stable energy, but the dominant story sold to the public was far simpler than reality. In this episode, Bret Kugelmass explains why the real bottleneck was never just climate ambition, but how the West misunderstood energy itself. For years, nuclear was framed as too dangerous, too slow, too expensive, and politically untouchable. Meanwhile, electricity demand kept rising, industrial resilience became strategic again, and the gap between energy ambition and physical reality widened. This conversation gets underneath the narrative. Bret Kugelmass, Founder and CEO of Last Energy, argues that the nuclear debate was never only about science or safety. It was also about incentives, regulation, public perception, delivery models, and the failure to distinguish what is inherent to the technology from what is imposed by the system around it. Drawing on his path from Silicon Valley entrepreneurship into deep energy infrastructure, Bret explains why he believes the West solved for the wrong variables, why wind and solar alone cannot carry modern industrial societies in many regions, and why the real breakthrough in nuclear may not come from reinventing the reactor, but from reinventing how power plants are built, sold, and deployed. As he puts it: (00:33:11) “Solve the wrong problem brilliantly and you’ll be the only one who cares.” This episode is not just about nuclear energy. It is about first-principles thinking, product-market fit in deep tech, and the kind of contrarian founder logic required to build where politics, infrastructure, and capital collide. What You’ll Learn in This Episode 1️⃣ Why Bret says the West misunderstood the real energy bottleneck 2️⃣ Why net zero may be the wrong framing for climate ambition 3️⃣ What most people still get wrong about nuclear waste, safety, and Fukushima 4️⃣ Why nuclear’s real challenge is cost and construction, not physics 5️⃣ How Last Energy reframed the business by selling electricity, not reactors 6️⃣ What founders can learn from solving the right problem before scaling Selected Timestamps (00:04:29) Introduction (00:04:29) Defining climate goals beyond net zero (00:13:46) Bret discovers nuclear mission and truth (00:19:44) Chernobyl versus Fukushima what truly matters (00:21:39) Nuclear's unmatched physics for abundant energy (00:30:08) Ideal world nuclear plants in 18 months (00:36:02) Solving the right problem before building (00:42:58) First principles simplicity as Last Energy’s edge (00:51:16) Securing 30 billion through true product market fit (00:54:05) Last Energy vision for tens of thousands of gigawatts (00:56:12) Taking ultimate responsibility to drive massive global progress 🎙️ Beginner’s Mind Top 10% globally. Conversations for founders, investors, executives, and policymakers shaping biotech, deep tech, energy, and industrial transformation. Follow the show for more long-form conversations on technology, capital, and the people building what the future will actually run on. Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

Most investors think they’re rational. Most founders think they’re disciplined. Most boards think they’re strategic. They’re usually wrong. In this episode, we unpack Fast Forward Thinking by Luis Pareras — a physician turned deep-tech venture capitalist who distilled decades of investing under scientific uncertainty into 40 brutally structured rules. This is not a summary. It’s a decision upgrade for founders, operators, board members, and capital allocators navigating the high-stakes terrain from Series A to IPO and beyond — where bias compounds, capital misallocates, and timing determines survival. Across seven tightly structured lessons, we explore how elite investors actually think: Why consensus is often a red flag Why opportunity abundance demands ruthless selectivity Why the first meeting should never close Why innovation compounds through milestones — not miracles Why exit logic must exist from day one Why managing error asymmetry beats being “right” And why teams — not ideas — determine survival under pressure This episode translates Pareras’ venture logic into executive practice — with direct applications for capital allocation, hiring, governance, and strategic design. You’ll walk away with frameworks, sharper filters, and board-level questions that immediately improve judgment. Key Takeaways Bias Is the Silent Capital Killer Consensus feels safe. It often destroys upside. Selectivity Is Survival Abundance demands disciplined rejection. Curiosity Beats Closure The first meeting earns the second. Innovation Is Staged Breakthroughs are milestone-based progressions. Exit Thinking Is Structural Capital is deployed against time horizons. Error Asymmetry Shapes Returns Managing Type I and Type II errors defines long-term performance. Teams Outperform Ideas Execution discipline and cognitive flexibility win under uncertainty. Timestamps (00:00) Introduction (04:17) The Big Idea (08:33) Who Is Luis Pareras (12:03) Takeaway 1: Cognitive Bias Is the Hidden Enemy of Good Decisions (18:55) Takeaway 2: Deal Flow Is Abundant — Selectivity Is the Real Skill (24:16) Takeaway 3: The First Meeting Is Not About Closing (29:04) Takeaway 4: Innovation Is a Process (35:20) Takeaway 5: Exit Awareness Shapes Investment Logic (39:59) Takeaway 6: Error Types Matter More Than Individual Outcomes (44:38) Takeaway 7: Teams and Judgment Matter More Than Ideas (49:15) Key Takeaways: The Fast Forward Operating System (54:25) Personal Reflection and End Why Listen Upgrade how you evaluate opportunities — before committing capital. Sharpen how you structure innovation — before chasing breakthroughs. Design decision systems that reduce catastrophic error. And build organizations that survive uncertainty. If this episode sharpens your thinking: Follow the show. Share it with someone who allocates capital. And bring these questions into your next board meeting. Because in venture, public markets, and corporate strategy alike — returns are rarely accidental. Send a text Support the show Join the Podcast Newsletter: Link

Most biotech breakthroughs don’t fail in the lab. They fail when science meets manufacturing reality. And by the time this bottleneck appears, tens of millions are already sunk. This episode examines the most under-discussed failure point in modern biotech: the gap between scientific discovery and scalable, usable healthcare solutions. While science has never been stronger—and big pharma excels at market access—companies that can translate breakthrough biology into industrialized medicines remain rare. Manufacturing, regulation, clinical design, usability for patients and physicians, and global scalability still form a narrow bottleneck where most value is lost. In this conversation, Björn Cochlovius, CEO of Eleva, explains why so many promising biologics fail late—and how Eleva deliberately built a platform designed not to replace existing systems, but to rescue projects that would otherwise be abandoned. Drawing on decades across immunology, biotech leadership, and translational medicine, Björn offers a grounded, operator-level view on what it actually takes to move from elegant science to real-world impact. As he puts it: (00:28:59) “In biotech, courageous decisions often look wrong—until years later.” This discussion goes beyond manufacturing alone. It explores why turning scientific concepts into ready-to-deploy healthcare solutions—complete with clinical data, regulatory pathways, scalable production, and high usability—remains one of the hardest industrial challenges of our time. What You’ll Learn in This Episode 1️⃣ Why biologics often fail late—after science already worked 2️⃣ Why manufacturing is only one part of a deeper industrial bottleneck 3️⃣ How Eleva approaches risk when others walk away 4️⃣ Why courage, not optimization, drives breakthrough biotech decisions 5️⃣ How AI supports discovery—without replacing human judgment 6️⃣ What Europe gets right—and still gets wrong—about scaling biotech 🧭 Selected Timestamps (00:03:00) Why biotech breakthroughs fail at manufacturing (00:07:18) Three takeaways for founders and investors short on time (00:08:36) Why biologics production breaks at scale (00:11:41) Salvaging proteins that standard systems cannot produce (00:15:27) The hidden opportunity in “failed” proteins (00:17:21) Why late-stage manufacturing failure destroys value (00:19:35) Why Eleva builds its own pipeline, not just a platform (00:22:46) Glycosylation as a source of better efficacy (00:27:03) Courageous decisions when everyone else has failed (00:30:04) Risk management through parallel scientific bets (00:32:08) Why similar proteins behave differently in patients (00:37:08) AI as a tool, not a replacement for human judgment (00:41:02) Why humans must remain accountable in drug discovery (00:44:25) The tension between basic research and development (00:46:01) Managing the handover between scientific universes (00:50:38) The CEO’s real job: building teams smarter than yourself (00:53:11) Leadership humility and protecting the team (00:56:11) How leaders recharge under long-term pressure (00:59:13) Europe’s biotech bottleneck and why there is still hope (01:02:20) Final reflection: turning science into systems that scale 🎙️ Beginner’s Mind Top 10% globally. Conversations for founders, investors, executives, and policymakers shaping the future of biotech, deep tech, and healthcare. Follow the show for more episodes where science meet Send us a text Support the show Join the Podcast Newsletter: Link

Nine out of ten startups fail, yet Europe keeps funding them the same way. Governments replace judgment with bureaucracy, capital replaces experience, and failure is misunderstood instead of learned from. This conversation exposes why venture capital is a profession, not a policy tool — and why getting this wrong quietly kills innovation. In this episode, Jim Pulcrano, Adjunct Professor at IMD and longtime venture investor, explains why most venture capital systems fail before capital is even deployed. Drawing on four decades across Silicon Valley, Europe, and academia, Jim dismantles the myth that VC success comes from spreadsheets, credentials, or government programs. Instead, he shows why pattern recognition, lived experience, and exposure to failure are the real differentiators. As Jim puts it: (01:13:27) “Silicon Valley is the world’s capital of failure — and also the capital of learning.” That mindset difference explains why Europe struggles to scale founders, why governments unintentionally create zombie companies, and why operators consistently outperform theorists when backing the next generation of companies. This is not a motivational episode. It’s a structural diagnosis of how innovation ecosystems actually work — and where Europe still gets in its own way. 💡 What You’ll Learn in This Episode 1️⃣ Why most venture capital fails long before money is invested 2️⃣ Why governments cannot replace judgment, experience, or risk-taking 3️⃣ Why operators outperform bankers as investors 4️⃣ Why failure is data — not stigma — in high-performing ecosystems 5️⃣ What Europe must change to unlock its next innovation cycle 👤 About Jim Pulcrano Jim Pulcrano is an Adjunct Professor at IMD with over four decades of experience across venture capital, entrepreneurship, and executive education. He has worked extensively in Silicon Valley and Europe, advising founders, investors, and institutions on scaling companies, leadership development, and venture capital as a professional discipline. 💬 Quotes (01:13:27) “Silicon Valley is the world’s capital of failure — and also the capital of learning.” (01:33:58) “You have to be there at midnight when you’re trying to make a decision on Sunday night.” (01:40:14) “I’ve never met a successful entrepreneur who hasn’t been weeks from running out of money.” (01:23:21) “A government purchase order is worth more than the same amount in cash.” 🧭 Timestamps (00:04:25) Why most startups fail — and why that’s not the real problem (00:09:55) Why Europe still misunderstands venture risk (00:16:42) Why founders matter more than ideas (00:24:13) Why governments create zombie startups (00:32:34) Why operator VCs outperform financial engineers (00:40:14) Failure as data, not disgrace (00:48:26) Why venture capital cannot be taught without simulation (01:04:48) What LPs should really look for in fund managers (01:19:46) Government as customer vs government as controller (01:30:10) Why young people should not rush into VC (01:32:38) Why empathy separates great investors from average ones (01:45:13) Leadership shifts from startup to scale-up (01:50:06) Three changes Europe must make now 🎙️ Beginner’s Mind Top 10% globally. The Send us a text Support the show Join the Podcast Newsletter: Link

Most goals don’t fail because of laziness or lack of ambition. They fail quietly — buried under daily noise, competing priorities, and forgotten intentions. By March, even the most meaningful goals have slipped down the list… replaced by urgency, meetings, and excuses. In the last years, whenever I work with companies or people in my executive coaching a pattern showed up frequently. In private life: marathons abandoned, educations postponed, mountains left unclimbed. In business: bold visions diluted, priorities scattered, companies losing momentum — not because the goal was wrong, but because it was never protected. This Year in Review 2025 episode is my answer to that problem. After working with founders, executives, and teams throughout the year, one truth became unavoidable: Big goals don’t fail because people stop caring. They fail because they lose daily contact. So I stripped goal-setting down to what actually works. To make it memorable, I revisited the conversations of 2025 and selected six voices — from politics, investing, entrepreneurship, and professional sport — each illustrating one essential principle for achieving meaningful goals. No hype. No motivational slogans. Just a clear, calm framework you can apply immediately to your most important goal for 2026. 🧭 What You’ll Learn in This Episode 1️⃣ Why discipline and motivation are overrated — and what replaces them 2️⃣ How goals quietly disappear without friction or resistance 3️⃣ Why choosing one goal is the highest-leverage decision you can make 4️⃣ How to keep goals present without pressure or obsession 5️⃣ Why process builds identity — and outcomes don’t 6️⃣ What real commitment looks like when nobody is watching ⏱️ Timestamps (00:00) Why New Year’s Resolutions Collapse — and What Actually Works (02:57) Karl Nehammer — “Sometimes there is no guidebook” (04:19) How Goals Quietly Disappear (07:56) Alex Dang — Focus, Selection, and Knowing When to Fold (11:45) Hack Away the Unessential — Choosing One Goal (14:05) Fabrizio Conicella — Skills Entrepreneurs Need in 2026 (17:54) Why You Must Review Goals Daily (19:43) Jason Foster — Setting Big Goals and Chipping Away (20:48) Process Over Outcome (22:48) Alasdair Milton — Doing the Work When Nobody Is Watching (26:05) Start Now — Before It Feels Comfortable (27:50) Vadim Fedotov — What Commitment Really Means (30:54) Before You Leave — Ed Sheeran’s Approach to Progress 🎙️ About This Episode This episode isn’t about setting more goals. It’s about protecting one goal that actually matters — whether you’re building the next NVIDIA, scaling a company, or working toward a personal milestone. If 2025 taught us anything, it’s this: Clarity beats intensity. Direction beats urgency. Process beats motivation. May 2026 be the year your most important goal doesn’t get lost. I’m glad you’re here. Send us a text Support the show Join the Podcast Newsletter: Link

Breakthrough science has never been stronger — yet patients still miss life-saving therapies. Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery. The problem isn’t discovery. It’s how science, capital, and systems are aligned — or not. Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem. As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge scientific depth with incentives, execution, and real-world delivery. Capital follows speed and scale — not intention — and healthcare systems built decades ago are failing to keep up. In this episode, Alasdair Milton, Principal at KPMG, explains where innovation actually breaks — and what must change for cures to reach patients at scale. From diagnostics and data silos to capital allocation and prevention models, this conversation reframes the next decade of precision medicine. 💡 What You’ll Learn in This Episode 1️⃣ Why only a fraction of eligible patients receive precision therapies 2️⃣ How delivery systems — not science — kill innovation outcomes 3️⃣ Why prevention is the next major value shift in healthcare 4️⃣ How capital allocation decisions quietly determine patient access 5️⃣ What leaders must change now to compete in the next biopharma cycle 👤 About Alasdair Milton Alasdair Milton is a Principal at KPMG advising global biopharma leaders on strategy, transactions, and innovation models. With a PhD in cancer biology and two decades at the intersection of science and capital, he works with executives navigating precision medicine, prevention, and large-scale healthcare transformation. 💬 Quotes That Reframe the Debate (01:00:20) “Great science only creates value when translated into clear commercial decisions.” (01:37:24) “Power has swung decisively to pharma, with biotechs now starved for capital and leverage.” (01:36:10) “Markets shift fast, but leverage always follows capital, data, and disciplined execution.” (02:26:30) “Life sciences must move from treating sickness to predicting risk and sustaining lifelong wellness.” (01:46:24) “China is catching up fast, and by the 2030s, truly innovative molecules may originate there.” 🧭 Timestamps (00:04:04) Shifting from treating disease to preventing it (00:05:32) Turbulent markets, steady scientific progress (00:07:03) In-vivo CAR-T and the next leap in cellular medicine (00:11:00) From chronic disease management to functional cures (00:20:20) Bridging specialized science with corporate strategy (00:21:55) Translating lab precision into business language (00:22:07) Bridging scientific depth to business acumen (00:57:40) Turning complex science into decisive commercial implications (01:08:46) Why in-person collaboration still drives leadership and learning (01:11:48) Navigating the $200B biopharma patent cliff through M&A (01:17:25) Capital concentrates on de-risked teams with proven leadership (01:18:17) Interpreting the biotech market recovery and tailwinds (01:28:26) Long-term capital returns as pharma reclaims deal leverage (01:38:03) Navigating IRA impacts and macro headwinds (01:43:39) China’s rapid ascent in the global monoclonal pipeline (01:46:24) China accelerates the eastward shift in global innovation (02:07:31) Precision medicine redefines individualized healthcare outcomes (02:09:03) Standardi Send us a text Support the show Join the Podcast Newsletter: Link

Most founders obsess over ideas. Breakthrough companies obsess over inflections, conviction, and structure. This episode unpacks Pattern Breakers by Mike Maples Jr.—a book that quietly explains why most startups never break out… and why a small minority reshape entire categories. But this isn’t a book summary. It’s a thinking upgrade for founders, operators, board members, and investors navigating the most fragile phase of company building: Series A to IPO, where timing, conviction, and structure matter more than features or pitch decks. Across seven tightly structured lessons, this episode explores how pattern-breaking companies are built before the world is ready for them—and why success is rarely about genius ideas, and almost always about seeing the future early and designing for it deliberately. You’ll hear why: external inflectionsnon-consensus and rightprototypes test desperationEach lesson is grounded in real company examples, translated into today’s market reality, and finished with coaching questions you can use immediately—in leadership meetings, boardrooms, or investment decisions. Key Takeaways Inflections Beat Ideas Breakthrough timing comes from external change, not creativity. Non-Consensus Is the Signal If everyone agrees, upside is already gone. Movements Outrun Products Identity compounds longer than features. Test Desperation, Not Interest Scalability starts with craving, not curiosity. Protect Conviction Consensus feels safe. It rarely creates breakthroughs. Design for Breakthroughs Small, protected, fast teams outperform bureaucracy every time. Timestamps (00:00) Intro (02:58) The Big Idea Behind Pattern Breakers (05:19) Who Is Mike Maples — and Why His Perspective Matters (07:35) Lesson 1: Start With Inflections, Not Ideas (12:36) Lesson 2: Be Non-Consensus and Right (17:31) Lesson 3: Prototype the Future, Not the MVP (21:31) Lesson 4: Recruit, Lead, and Scale Through Movements (26:20) Lesson 5: Master Productive Disagreeableness (30:04) Lesson 6: Break the Corporate Biases That Kill Breakthroughs (35:00) Lesson 7: Structure for Breakthrough Execution (39:41) Key Takeaways — The Lenses and Habits That Matter (42:21) Personal Reflection & Critique Why Listen beforeFound this valuable? Like, share, and follow. Every signal helps grow the show—and brings you more thinking frameworks from people and companies who didn’t follow patterns… they broke them. Send us a text Support the show Join the Podcast Newsletter: Link

The world has grown quiet about climate change. Too quiet. We scroll past floods, fires, droughts… and move on with our day. As if the problem solved itself. As if we’ve earned the luxury to look away. Janos Pasztor has spent 40 years inside the rooms where climate decisions are made — from serving as UN Assistant Secretary-General for Climate Change to advising presidents, prime ministers, and global institutions. And in this SPARK20 highlight episode, one truth stood out: We are not done with climate change. We are only entering its most consequential chapter. This is not a doom story. It is the story of a man who still believes humanity can choose a better future — if we’re willing to face the questions we’ve been avoiding. What You’ll Learn in 20 Minutes Why global warming accelerates even as we reduce emissions (00:01:15) And why governments are still “not addressing the issue sufficiently.” Why adaptation alone cannot save us (00:01:54) And what the real limits of adaptation look like. Why Janos believes we may need to cool parts of the planet (00:02:32) And why no political leader wants to say it out loud. How climate diplomacy changed since the 1980s — and why it matters now (00:03:32) Including the rise of China in global negotiations. Why capitalism itself may need to evolve (00:08:05) And what this means for investors, innovation, and global stability. What geoengineering really is (and is not) (00:09:16) Forget the internet myths — this is the factual explanation. Why volcanic eruptions hold a clue to future climate solutions (00:12:04) Why SRM is scientifically feasible — and politically dangerous (00:17:11) The technology is simple. The governance is not. Why the biggest risk of SRM is not cost — but consent (00:17:44) And what happens when societies don’t get a say. What a unilateral climate intervention could trigger (00:20:33) A scenario every policymaker should hear. Why Janos still believes in a brighter future (00:21:07) A rare moment of optimism from someone who has seen every side of the crisis. Quotes to Carry With You 📌 “Global temperatures continue to rise — and the world is not ready.” (00:01:15) 📌 “We must consider whether the time has come to start cooling parts of the planet.” (00:02:32) 📌 “Three degrees of warming is cuckoo land. You simply cannot adapt to that.” (00:18:23) 📌 “Technology is not the issue. It’s cheap. The real question is: do societies want this?” (00:17:11) 📌 “I wouldn’t be here if I didn’t believe we can still get this right.” (00:21:07) Why This Conversation Matters Because climate change isn’t a chapter we finished. It’s the foundation on which every other chapter of the future will be written — our economies, our food systems, our borders, our investments, and the lives of our children. And while Elon Musk may one day take humans to Mars, no one alive today will move there. This planet is the one we must keep habitable. Janos Pasztor is a reminder that realism and hope are not opposites — they’re partners. 👉 Listen now. Share it forward. Keep the conversation alive. Send us a text Support the show Join the Podcast Newsletter: Link

Europe leads the world in discovery — yet too often, its breakthroughs never become global companies. Billions in research funding turn into patents, not products. While others build empires from ideas, Europe risks becoming the world’s laboratory — brilliant, but broke. That’s the paradox at the heart of this conversation. In this episode, Karl Nehammer, Vice-President of the European Investment Bank (EIB) and former Chancellor of Austria, joins Christian Soschner live at BIO-Europe 2025 to discuss how Europe can turn its world-class science into world-class companies. He shares how leadership forged in crisis can rebuild confidence, competitiveness, and growth — and why every crisis hides an opportunity to start thinking differently. 💡 What You’ll Learn in This Episode 1️⃣ Why Europe’s innovation system struggles to turn discovery into scale 2️⃣ How the EIB can bridge the gap between science, capital, and market impact 3️⃣ Lessons from leading through COVID-19, the energy crisis, and diplomatic challenges 4️⃣ Why changing culture and regulation is key to Europe’s competitiveness 5️⃣ The mindset Europe needs to move from surviving to building 💬 Quotes from Karl Nehammer 🧭 Timestamps (00:00:00) Opening – Why Europe Struggles to Scale (00:03:33) Karl Nehammer – Leadership Lessons from Crisis (00:06:21) Europe’s Innovation Challenge – Science vs. Commercialization (00:09:17) Life-Science Resilience – Lessons from COVID-19 (00:12:52) A Realistic Vision for Europe’s Future (00:17:05) Inside the European Investment Bank – Building Bridges Between Capital and Innovation (00:18:59) Empowering Founders – Karl Nehammer’s Message to Europe’s Builders (00:20:14) Closing – Optimism, Collaboration, and Confidence 🎙️ Beginner’s Mind Top 10% globally. The leading podcast for founders, investors, and policymakers shaping the future of biotech, deep tech, and innovation. Follow the show to explore more conversations like this one — where science meets strategy and leadership builds the future. Send us a text Support the show Join the Podcast Newsletter: Link

Most founders dream of raising millions. Few survive the 153 “no’s” it takes to get there. Behind every biotech breakthrough lies exhaustion — late-night calls, failed rounds, and investors who walk away at the finish line. What separates the ones who make it isn’t luck or timing — it’s resilience built into process. In this episode, Jason Foster, CEO of Ori Biotech, shares how he transformed relentless rejection into a billion-dollar trajectory. From rebuilding cell-therapy manufacturing to leading global teams through economic storms, Jason reveals how founders can systematize grit, master storytelling, and survive when everything seems to fall apart. You’ll learn how to navigate fundraising winters, why leadership begins with self-care, and how to build companies that endure long after the hype fades. If you’ve ever doubted your path as a builder, this conversation will remind you that resilience is not a trait — it’s a practice. 💡 What You’ll Learn in This Episode 1️⃣ The real reason most founders fail long before capital runs out 2️⃣ How to turn rejection into momentum using process and habit 3️⃣ Why storytelling is the most underrated skill in biotech leadership 4️⃣ How resilience and self-care directly drive performance and valuation 5️⃣ The mindset that separates enduring companies from short-term success 👤 About Jason Foster Jason Foster is the CEO of Ori Biotech, a leading innovator transforming cell and gene therapy manufacturing. With 20+ years in global health, he has raised over $140M, led companies through IPO-level growth, and serves as a mentor and investor to emerging founders in life sciences. His mission: make advanced therapies accessible to every patient, everywhere. 💬 Quotes That Might Change How You Think (00:14:09) “There are cures for cancer today, but patients can’t reach them — access must change.” (00:37:22) “The science is extraordinary — but if we can’t make it at scale, it means nothing.” (01:22:17) “Purpose, not money, drives talent to transform lives through innovation.” (01:46:17) “Fundraising is a war of attrition — constant rejection tests your resilience more than your idea.” (02:02:16) “You only have to get up one more time than you’re knocked down.” 🧭 Timestamps to Explore (00:02:00) Embracing Hard Challenges — How Biotech Founders Build Resilience That Lasts (00:13:40) The Unacceptable Truth: Cures Exist, Yet Patients Still Can’t Access Them (00:26:23) Navigating Cultures — What European and American Biotech Leaders Can Learn From Each Other (00:32:52) Why Great Science Isn’t Enough Without Commercial Viability (00:39:19) Revolutionizing Cell Therapy Manufacturing — The Seven-Day Bottleneck Explained (00:50:11) Automation and Digitization — Unlocking Scalable Patient Access in Cell and Gene Therapy (01:09:30) Rethinking Capacity Utilization — Making Regional Biotech Manufacturing Centers Work (01:14:27) Mass Personalization — The Future Delivery Model for Advanced Therapies (01:23:00) Purpose-Driven Talent — The Secret to Retaining Top Biotech Performers (01:32:18) Fundraisin Send us a text Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

Imagine waking up to find your company’s most valuable IP leaked—not by hackers, but by the very AI tools you trusted. This isn’t a distant scenario; it’s happening inside pharma and biotech right now. And the cost isn’t just financial—it’s patient lives, broken trust, and an industry on the edge of losing credibility. In this episode, Kat Kozyrytska shares how leaders can act before invisible risks become catastrophic. From her personal journey in post-Soviet Ukraine to building frameworks in global biotech, Kat reveals why “yesterday problems” with AI demand urgent attention today. You’ll learn how data privacy failures propagate quietly, why embedding organizational values into AI is essential, and how collaboration across companies can safeguard innovation and accelerate therapies. The future of biotech won’t be secured by hype or speed—but by trust, ethics, and the courage to act before it’s too late. 🎧 What You’ll Learn in This Episode 1️⃣ Why “yesterday problems” with AI in pharma are already costing billions 2️⃣ How data privacy failures silently erode trust, IP, and patient safety 3️⃣ The difference between collaboration and competition in biotech innovation 4️⃣ Why embedding organizational values into AI is no longer optional 5️⃣ The future of drug discovery, clinical trials, and manufacturing in an AI-first world 👤 About Kat Kozyrytska Kat Kozyrytska is the Founder of the Cell Therapy Manufacturability Program and a global thought leader at the intersection of biotech and AI. With roots in Ukraine and a career spanning MIT, Stanford, Thermo Fisher, Sartorius, and global biotech startups, she bridges technical depth with ethical foresight. 💬 Quotes That Might Change How You Think (00:14:50) "AI can amplify good or bad behaviors — the choice is ours." (00:38:14) "Discovering dark personalities is like learning Santa isn’t real — traumatic, but suddenly everything makes sense." (01:03:26) "AI speaks with absolute confidence, but confidence is not the same as truth." (01:20:22) "AI gives us a rare chance to embed ethics and values into innovation." (01:57:01) "If personalized therapies work better, we have an ethical duty to deliver them." 🧭 Timestamps to Explore (00:05:16) From Math to Medicine – Kat’s unexpected path from equations to biotech leadership (00:09:38) Inside a Nobel Lab – How neuroscience breakthroughs shaped her ethical lens (00:12:27) Shadow AI – Why biotech leaders can’t wait to govern hidden systems (00:23:03) Data Sharing Paradox – Collaboration vs confidentiality in pharma innovation (00:31:31) Neurobiology of Manipulation – How dark personalities exploit human trust (00:41:18) Hidden Privacy Risks – What your everyday data footprint really reveals (00:52:17) Soviet Control vs American Individualism – Lessons for AI governance today (00:57:30) The Danger of One Answer – Why converging on a single AI truth is risky (01:02:51) Confidence ≠ Expertise – Rethinking how we trust AI in science (01:18:16) Embedding Core Values – How leaders can align AI with human ethics (01:51:28) Breaking Down Silos – Th Send us a text Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

Most founders obsess over products. Jensen Huang built a $3 trillion company by obsessing over inevitabilities. This episode unpacks The NVIDIA Way by Tae Kim—the definitive account of how NVIDIA went from near-death startup to the world’s most valuable chipmaker. More than a history, it’s a manual for founders and VCs navigating the messy, high-stakes stretch between Series A and IPO. But this isn’t just about NVIDIA. It’s about you—if you’re scaling in deep tech, where survival depends less on genius inventions and more on how you engineer resilience, culture, and urgency into your system. I walk you through 7 scaling lessons that matter now—from why pain is a founder’s greatest teacher to how vision and culture become moats no competitor can copy. Each principle is grounded in NVIDIA’s story, translated into today’s market reality, and wrapped with coaching prompts you can act on this week. Key Takeaways: Timestamps: (00:00) Why This Episode Matters (02:18) The Big Idea of The NVIDIA Way by Tae Kim (04:36) Who is Tae Kim? (08:15) Lesson #1: Pain and Suffering Are the Recipe for Greatness (12:35) Lesson #2: Your Reputation Is Your Currency (17:05) Lesson #3: The Innovator’s Dilemma Will Come for You (21:45) Lesson #4: Lead With Context, Not Control (25:18) Lesson #5: Don’t Just Sell the Product—Sell the Vision (30:00) Lesson #6: Culture Outruns Capital—and the Competition (34:32) Lesson #7: Build Urgency Into the System (38:30) Key Takeaways—3x Reading + 25 Years in Public Markets, VC, and Scaling Deep Tech (41:24) Reflection Why Listen: Found this valuable? Like, share, and follow. Every signal grows the show—and helps bring you more playbooks from the world’s most resilient companies. 🎙️ - Beginner's Mind. Top 10% global. #1 deep tech podcast. 200+ episodes. Send us a text Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

How do you succeed in a business where being wrong is the norm? Marc Penkala has lived both sides of the table: as an entrepreneur who built, sold, and failed with companies—and now as a venture capitalist running his own fund. What makes his story different is the radical honesty about what actually drives success in venture: failure, timing, and taking risks that look stupid at first. This Spark20 episode distills Marc’s hard-earned lessons into a 20-minute masterclass for founders, investors, and policymakers navigating uncertainty. What you’ll learn Timestamps & Quotes 📌 (00:00:38) Entrepreneur → VC “My route into venture capital felt like a paid executive MBA… I built, I sold, I bankrupted, and then I joined the so-called evil side to truly understand investors.” 📌 (00:03:31) Failure as Fuel “Failure is the bigger success… many of my failures turned into the best things that ever happened.” 📌 (00:05:32) Credibility Through Scars “If I had never built a company, how could I authentically tell a founder I can help them?” 📌 (00:07:29) Wrong = Right in Venture “As a VC, you’re more often wrong than right. And strangely, the more you’re wrong, the higher your actual output.” 📌 (00:10:38) When Tourists Arrive, Leave “The moment angels and LPs with no clue flood the market, you literally have to stop investing. That’s when the tourists arrive.” 📌 (00:12:22) Outliers Make the Portfolio “One angel had ten bets—two of them gorillas and Tier. Didn’t matter what else he had—the outliers alone defined him.” 📌 (00:13:02) Europe vs. US Mindset “US startups think in billions. European startups think in millions. That mentality shift is everything.” 📌 (00:15:02) Stupid Ideas Win “If everyone agrees it’s a great deal, don’t do it. The best investments sound like the stupidest idea at first.” 📌 (00:17:42) Why Down Markets Build Giants “In down markets, founders get humble, go back to fundamentals, and focus on capital efficiency. That’s why the best companies come from downturns.” Endnote This isn’t just a highlight reel—it’s a reminder that in venture capital and entrepreneurship, the rules are upside down. Being wrong isn’t a weakness—it’s proof you’re taking the swings that matter. 👉 Listen now, and share it with someone who needs to think bigger. 🎙️ With over 200 interviews, panels, and livestreams, Beginner’s Mind ranks in the Top 10% globally—and is recognized as the leading deep tech podcast for Send us a text Support the show Join the Podcast Newsletter: Link

Here’s the harsh truth: If your business model can’t survive a spreadsheet, it won’t survive the market. Every year, ambitious founders pour months into product, pitch, and brand—yet the single biggest reason startups die isn’t funding, it’s flawed modeling. What are the four variables investors use to spot winners before anyone else? In this episode, investor and hands-on builder Alex Oppenheimer (Founder & GP at Verissimo Ventures, ex-Facebook IPO, ex-NEA, Monday.com advisor) reveals why most startup advice misses the point—and how the best founders reverse-engineer success long before a single euro is raised. 🎧 Watch now to learn: 1️⃣ The business model simulation Alex uses to kill (or greenlight) a deal in under an hour 2️⃣ The one thing top VCs always ask founders—but almost nobody prepares for 3️⃣ Why a founder’s “calling” is more important than their credentials 4️⃣ How to avoid the European trap of ignoring leverage and failing to scale 5️⃣ The subtle mindset shift that separates bold investors from the herd—and how to apply it to your own company 👤 About Alex Oppenheimer Stanford-trained engineer, ex-Morgan Stanley tech banker, NEA Series A investor, Monday.com operator, and now founder of Verissimo Ventures—a fund that bets on weird tech and next-gen software models in Israel, the US, and Europe. 💬 Quotes That Might Change How You Think: (00:59:00) “If I don't build this, nobody else will—that’s the founder’s true calling.” (01:12:45) “How can you know what data to collect if you don’t know the model?” (01:22:36) “The real job of an investor is helping great founders not mess it up.” 🧭 Timestamps to Explore: (00:04:00) Quitting Corporate Venture—The Decision That Changed Everything (00:11:50) What Business Modeling Is (and Isn’t) (00:18:30) Trusting the Founder Over the Deck (00:24:40) Venture Capital and the Power of Naivete (00:34:03) Inside the Facebook IPO Data Room (00:44:38) Lessons from Betting on Outliers (00:49:48) Leaving NEA to Build Israel’s Next Scaleups (01:02:32) From Frustration to Founding a Venture Fund (01:10:57) Why Business Modeling Remains a Blind Spot (01:14:09) Redefining Value Investing in Venture Capital (01:15:50) Decoding Value with Core Variables (01:22:36) Helping Founders Avoid Unnecessary Pitfalls Early 🔔 Like what you hear? Follow the show and share this episode with one builder, founder, or investor you respect. Every share helps us bring new industry leaders and sharper insights straight to you. Subscribe now—your next breakthrough could be one episode away. 🎙️ Beginner’s Mind Top 10% globally. The leading podcast for VCs, operators, and anyone obsessed with building what comes next. Send us a text Support the show Join the Podcast Newsletter: Link

Why do Europe’s brightest founders still feel forced to leave for Silicon Valley—no matter how much money or talent we pour into the region? Every year, ambitious startups across Europe and CEE struggle to scale—not for lack of ideas, but because of invisible barriers that keep global success out of reach. Is it really just about capital—or is there a deeper mindset and playbook that only a handful of founders ever discover? In this episode, venture insider Enis Hulli (General Partner at e2vc, investor in 40+ startups, 3 unicorns, and builder of bridges from Istanbul to the Bay) pulls back the curtain on the real reasons US-based startups keep winning—and how founders from Turkey, Eastern Europe, and beyond can finally turn the tables. 🎧 Watch now to learn: 1️⃣ The “power law” that decides which founders build generational companies—and why most never see it coming 2️⃣ Why relationships, not pitch decks, determine who actually gets funded—and how to break through if you don’t have the right connections 3️⃣ How emotional resilience and founder mindset shape the fate of entire regions—not just individuals 4️⃣ The little-known risks of playing the European “safe game”—and how to engineer luck for outsized results 5️⃣ Tactical lessons on team building, brand, and why your anti-portfolio (the deals you missed) might matter even more than your winners 👤 About Enis Hulli Enis is General Partner at e2vc, a leading early-stage venture fund focused on scaling tech startups from Emerging Europe to global markets. With investments in 40+ companies (including three unicorns), he’s spent his career helping founders unlock the path from local player to world-class leader. 💬 Quotes That Might Shift Your Thinking: (01:30:44) “I don’t think we’ll see founders choosing Europe over the US in our…” (01:34:37) “There are twenty different ways to kill a reputation on any side of the…” (01:38:31) “To avoid complacency, I surround myself with people who make me feel like I…” 🧭 Timestamps to Explore: (00:16:58) How the Bay Area’s Talent Network Effect Became Unstoppable (00:20:48) Work-Life Balance vs. Blitzscaling—What It Really Takes to Go from Zero to One (00:25:43) Why Founders Trump Pitch Decks Every Time (00:30:38) The Perils of Planning for an Exit Too Soon (00:34:34) The Three Qualities Every VC Looks For—And Why Mindset Still Wins (00:40:30) How IPO Markets Shape (and Break) Venture Capital (00:43:52) Fundraising Mistakes That Kill FOMO and Crush Deals (01:12:58) Why Bay Area Mindset Still Outpaces Europe’s Best (01:30:44) The Real Reason Europe Loses Its Unicorns (01:34:37) Reputation, Relationships, and the Hidden Dangers of VC Control (01:38:31) How Top Investors Avoid Complacency and Stay Hungry 🔔 Follow the show and leave a review. Every follow, like, and share brings new global voices, industry leaders, and sharpest insights straight to you. 🎙️ Beginner’s Mind ranks in the Top 10% globally—and is recognized as the leading deep tech podcast for scientific entrepreneurship. Send us a text Support the show Join the Podcast Newsletter: Link

Still trying to optimize your health with guesswork and generic advice? Most people settle for “one-size-fits-all” supplements and hope for the best-missing out on the breakthroughs that only real data and personalization can offer. In a world flooded with empty promises, few realize how quickly tailored, science-backed solutions can transform energy, focus, and longevity. Enter Vadim Fedotov—ex-pro athlete, CEO, and co-founder of Bioniq, the health tech company bringing truly personalized care to the world’s top leaders, innovators, and athletes. In this eye-opening conversation, Vadim reveals why your biology is as unique as your fingerprint—and why the future belongs to those who personalize, measure, and adapt. Discover the systems, mindsets, and science behind optimizing human potential—without wasting time, money, or hope on outdated approaches. 🎧 Watch now to explore: 1️⃣ The fatal flaw in “one-size-fits-all” wellness—and how personalization is rewriting the rules 2️⃣ How AI, data, and regular feedback loops empower you to outpace your peers—at work, in health, and in life 3️⃣ Lessons from elite sports: why discipline, team dynamics, and feedback matter in business 4️⃣ The “feedback loop” secret that’s changing the supplement industry forever 5️⃣ Vadim’s vision for a future where your fridge, wearable, and AI coach work together to help you thrive 👤 About Vadim Fedotov Vadim is the co-founder and CEO of Bioniq, former CEO at Groupon, and a former professional basketball player with the German National Team and Buffalo Bulls. Driven by his passion for health optimization, he’s building a global, interdisciplinary network of thought leaders to put cutting-edge, personalized care within everyone’s reach. 💬 Quotes That Might Shift Your Thinking: (00:08:27) "Personalized health isn't a trend; it's the future of wellness." (00:15:54) "There is no single right diet, exercise, or routine—every body truly needs something different." (00:44:11) "Personalization in health is not a luxury anymore; it’s quickly becoming a necessity." (01:06:26) "You only fail when you give up—resilience defines success." (01:23:21) "Seventy percent of your health is determined by nutrition, not pharmaceuticals or medicine." 🧭 Timestamps to Explore: (00:03:32) Why Visionary Leaders and Families Move to Dubai (00:08:27) Personalizing Health Revolution How Data-Driven Wellness Changes Everything (00:09:27) Health as the New Wealth Post-Covid Insights (00:15:52) Busting Health Myths There’s No One-Size-Fits-All (00:18:28) Data Over Opinion Navigating Health Complexity (00:21:03) Olympic Research Sparks Personalized Health Innovation (00:23:51) When Obvious Solutions Don’t Exist—The Birth of Bioniq (00:25:40) When a "Dumb Idea" Becomes a Massive Opportunity (00:31:01) Setting Personal Health Goals With AI and Data (00:34:40) Real-World Feedback Loops Cut Through Wellness Hype (00:40:07) Data-Driven Breakthroughs That Save Lives (00:44:11) Why Health Personalization Is Now a Necessity (00:54:31) Leadership, Discipline, and Lessons from Elite Sports (01:01:04) Finding Pride and Resilience Against All Odds (01:23:21) Redesigning Healthcare Starting With Nutrition 🔔 Let’s Change the Future of Health—Together Follow the show. Leave a review. Share it with someone who’s ready to live—and lead—at their highest level. 🎧 Watch now and start your journey to real Send us a text Support the show Join the Podcast Newsletter: Link

How do you lead at the cutting edge of health, data, and AI—while staying deeply human? Angeli Möller has led global data science teams across pharma giants, co-founded one of Europe’s most ambitious AI alliances, and now builds high-performance biotech strategies with precision. But what truly sets her apart isn’t just her technical fluency—it’s her clarity, courage, and care in how she builds teams, solves problems, and pushes the boundaries of innovation. In this episode, Angeli opens up about the quiet frustrations that fuel her mission, the invisible cost of ignoring innovation, and the principles that guide her client work today. Whether you’re an investor, founder, or policymaker, her journey will reshape how you think about leadership, AI, and what truly moves the needle in healthcare. Here’s what you’ll take away: At the center of it all: a calm, fiercely smart leader who sees through the noise and builds what matters. As she says: “Start with the real problem. If you don’t understand the problem, AI won’t help you.” Timestamps & Topics 📌 (01:08) Missed AI Integration Costs – “It’s faster, more effective, cheaper—but it’s not part of the core business yet.” 📌 (03:57) AI vs. Real-World Drug Impact – “The question isn’t: does it use AI? It’s: does the medicine work?” 📌 (04:48) Post-Hype AI Fallout in Pharma – “Fraud led to disillusionment. And investors paid the price.” 📌 (06:39) Corporate Blind Spots in Innovation – “It’s a danger in business to think there’s nothing to learn from others.” 📌 (09:40) Building a European AI Alliance – “At first, pharma didn’t take us seriously. That changed with the data.” 📌 (11:02) Data Ethics and Regulatory Risk – “You can massively hurt your business through accidental bias.” 📌 (13:19) Data Access for Rare Diseases – “The only solution is to make that data safely available.” 📌 (15:22) Leadership Shift: From Bayer to Startup – “It felt too obvious. I needed something riskier, more meaningful.” 📌 (21:23) Three Core Leadership Traits – “Vision. Technical understanding. And knowing when to bring in others.” 📌 (22:27) Frictionless Health Tech Adoption – “It’s inevitable. The economics—and behavior nudges—are already shaping it.” This episode offers more than insight—it’s a playbook for building what’s next in health, tech, and leadership. 👉 Listen now, and share it with someone ready to shape the future. Send us a text Support the show Join the Podcast Newsletter: Link

Most founders add layers to gain control. Reed Hastings built an empire by removing them. This episode unpacks No Rules Rules—the leadership playbook behind Netflix’s rise from a DVD mail service to a global entertainment powerhouse. Co-authored by founder Reed Hastings and INSEAD professor Erin Meyer, the book reveals how to scale not through policy, but through trust, talent density, and extreme transparency. But this isn’t just about Netflix. It’s about you—if you’re building or investing in companies between Series A and IPO, where culture either compounds performance or quietly kills it. I walk you through 7 operational principles that deep-tech teams can apply now—lessons forged in crisis, growth, and reinvention. You’ll learn how to sunshine mistakes, pay like a pirate, and lead without becoming a bottleneck. Each principle is translated into coaching prompts, ready to implement this week. Key Takeaways: Culture Outruns CapitalPro Team > FamilyCandor Drives SpeedPay Top of MarketBet BoldlyContext Beats ControlTransparency = TrustTimestamps: (00:00) Intro – Why Netflix Scaled Faster by Removing Rules, Not Adding Them (04:30) Who Is Reed Hastings? – From Math Teacher to Global Disruptor (09:13) Book Snapshot – What Makes No Rules Rules a Real Operating System (11:35) Lesson 1: Culture Outruns Capital – How Netflix Survived 4 Disruptions, Blockbuster Didn’t Survive One (17:25) Lesson 2: Build a Pro Team, Not a Family – Talent Density Over Loyalty (22:48) Lesson 3: Radical Candor = Speed – The Feedback Model That Fuels Innovation (27:34) Lesson 4: Pay Like a Pirate – Why Netflix Pays Top of Market—No Games, Just Outcomes (32:20) Lesson 5: Bet Bold, Fail Proudly – The 4-Step Innovation Cycle That Keeps Netflix Ahead (39:12) Lesson 6: Lead with Context, Not Control – Scaling Leadership Without Becoming a Bottleneck (43:28) Lesson 7: Transparency Builds Velocity – How Truth-Telling Became Netflix’s Superpower (48:15) 7 Key Takeaways – The Culture Playbook Every Growth-Stage Founder Needs (50:15) Personal Reflection – What I Questioned, What I’ll Steal, What Gave Me Pause (52:00) Call to Action + What’s Next – Support the Show + Tease of the Next Episode Why Listen: Found this useful? Like, share, and follow. Every signal grows the show—and brings in more elite guests ready to share the truths behind high-growth success. Send us a text Support the show Join the Podcast Newsletter: Link

Most cancer drugs fail. Not because the science is wrong—because we’re solving the wrong problems. The cost? Over $2 billion per failure. And for the patient waiting on a miracle—there’s no second chance. Behind the headlines of “precision medicine,” there’s a deeper story nobody’s telling. Until now. 🎯 Enter Rafael Rosengarten, the scientist-turned-founder who’s rewriting the rules of drug development. In this gripping conversation, we unpack how RNA, AI, and deep empathy could finally close the loop between biology, data, and the patient in the room. 🎧 Watch now to explore: 1️⃣ Why drug failure isn’t a tech problem—it’s a strategy problem 2️⃣ How “information companions” will guide every medicine to the right patient 3️⃣ What pharma keeps getting wrong about biomarkers—and how to fix it 4️⃣ The untold story behind turning down a chef’s job on a Mediterranean yacht 5️⃣ The real reason Genialis may one day go out of business (and why Rafael hopes it does) 👤 About Rafael Rosengarten Rafael is CEO and co-founder of Genialis, the RNA biomarker company reshaping precision oncology. From academic labs to Michelin-star kitchens, his journey is anything but linear—but his mission is clear: make medicine make sense. With partners across pharma, diagnostics, and AI, Genialis is creating a world where every patient gets the treatment they actually need. 💬 Quotes That Might Shift Your Thinking: (00:58:37) “Our AI biomarkers de-risk clinical trials, slashing costs and saving lives.” (01:54:46) “Every drug will have an information companion guiding it to the right patient.” (01:14:32) “AI should free humans for empathy and creativity, not replace them.” (00:14:13) “We now have the tools to treat every cancer as unique to each patient.” (01:31:38) “Stop selling technology; sell solutions to real problems.” 🧭 Timestamps to Explore: (00:03:52) Inside the World’s Largest Medical Center (00:10:30) How AI Is Rewiring Precision Medicine (00:13:51) Why Precision Medicine Is Scaling Now (00:17:34) Startups Must Solve Market Needs First (00:23:53) Culture First, Then Business: Startup Blueprint (00:27:57) Cancer Isn’t One Disease—It’s Thousands (00:31:44) Predicting Drug Success with AI Biology (00:36:40) Reimagining Biomarkers Using RNA and AI (00:47:45) Why Early Detection Still Saves Lives (00:57:30) Why Most Cancer Drugs Still Fail (00:58:37) AI Biomarkers That De-Risk Clinical Trials (01:09:42) Rethinking Dosage with Predictive Algorithms (01:13:33) Why Human Intuition Still Matters in Science (01:36:41) The Crystal Ball Question Pharma Can’t Ignore (01:50:19) The moment where time disappears—and the real future begins. (01:53:39) Every Drug Will Have an AI Companion 🔔 Let’s Rebuild Trust in Medicine—Together If this episode sparked a new thought—or just gave you pause—don’t let it end here. Subscribe. Share it with someone who still believes medicine can be both scientific and deeply human. Every action brings in minds like Rafael’s… and gets us one step closer to treatments that truly heal. 🎧 Watch now—and discover how medicine gets smarter, safer, and more personal. Send us a text Support the show Join the Podcast Newsletter: Link